Low expression of total TFPI (α + β) showed significant association with decreased overall survival when considering all breast cancer subtypes together (all tumors) (P = 0.015), and the effect was even more profound in the high-proliferative poor outcome classes; HER2-enriched (P = 0.004) and lymph node-positive cancers (P = 8*10−5) (Figure 3A). The gene discussed is ERBB2; the disease is breast cancer.